April 18, 2013 — iCAD Inc. has entered into strategic distribution agreements for its Xoft Axxent Electronic Brachytherapy System with Chindex Medical Limited in China and with Medvio in Russia. The company also announced that the first breast cancer patient was treated with intraoperative radiation therapy (IORT) using the Xoft system in Taiwan.
“Breast cancer is predicted to be the most common cancer in Chinese women over the next 20 years. The availability of the Xoft System in China, including Hong Kong and Macau, will provide our customers access to the most advanced cancer treatments, including intraoperative radiation therapy for early stage breast cancer,” said Elyse Beth Silverberg, chief operating officer of Chindex.
The Xoft System is a mobile and flexible therapy option that can dramatically reduce treatment times. When used for IORT, the Xoft System delivers a single, prescribed, targeted dose of isotope-free radiation directly to the tumor cavity during surgery, thereby minimizing radiation to healthy tissue and organs and eliminating the need for a shielded treatment environment.
“In Russia there is a significant patient population that has difficulty accessing care. With the Xoft System, physicians will be able to use advanced technology to treat many more patients with breast, endometrial and cervical cancer,” said Lori Woods, principal, Medvio. “We’re excited to bring this breakthrough technology to physicians and patients in this rapidly growing market.”
For more information: www.xoftinc.com, www.icadmed.com
July 25, 2024 
